Oculis Holding AG Ordinary Shares OCS 深 滬
已收盤 07-18 16:00:00 美东时间
17.50
-0.670
-3.69%
華盛通- 最 高18.36
- 今 開17.89
- 成交量 3.07万股
- 最 低 17.22
- 昨 收 18.17
- 總市值 8.93亿
- 52周最高 23.08
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 10.79
- 委 比 0.00%
- 總股本 5103.37万
- 歷史最高 23.08
- 量 比 3.42
- 振 幅 6.27%
- 歷史最低 6.26
- 每 手 1
- 風險率 3.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多固态电池材料抢滩战：道氏技术从正负极到电解质全面覆盖，出海风险仍需警惕
本文来源：时代商业研究院 作者：陈佳鑫 来源|时代商业研究院 作者|陈佳鑫 为了能在下一代电池技术竞赛中胜出，电池企业正在加速全固态电池材料布局。近期...
07-16 22:41
Liminatus Pharma Enters MOU With Samda Biolab And INNOCS AI To Advance CA19-9-Combined INNOCS Diagnostic Platform For Early Pancreatic Cancer Detection
Liminatus Pharma, Inc. has entered into a Memorandum of Understanding (MOU) to form a research and development consortium with Samda Biolab Co., Ltd. and INNOCS AI, aimed at advancing a novel blood-based diagnostic kit
07-03 23:45
光模块行业专家交流
（转自：纪要头等座） 光模块行业专家交流 全文摘要 1、800G光模块行业需求预测 ·2025-2026年需求增长：2024年800G光模块出货量约900 1...
06-30 17:53
Regeneron and Sanofi Win FDA Approval for Dupixent to Treat Painful Skin Disease in Elderly Patients
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult patients with bullous
06-20 15:30
东方电子获得发明专利授权：“一种基于双活架构的备自投压板自动投退系统及投退方法”
证券之星消息，根据天眼查APP数据显示东方电子（000682）新获得一项发明专利授权，专利名为“一种基于双活架构的备自投压板自动投退系统及投退方法”，专利申请号为CN202411585853.6，授权日为2025年6月10日。
06-11 02:42
Oculis Publishes Results of 2025 Annual General Meeting
Oculis Holding AG announced the outcomes of its 2025 Annual General Meeting, where shareholders approved all agenda items, including the 2024 Annual Report, financial statements, and compensation plans. The company reported a standalone loss of CHF 5.179 million for 2024, with the accumulated loss of CHF 46.577 million carried forward. Directors and executives were discharged, and key personnel were re-elected. Shareholders approved compensation ...
06-05 08:00
Oculis to Participate in Upcoming June Investor Conferences
ZUG, Switzerland, June 03, 2025 — Oculis Holding AG, a global biopharmaceutical company, announced its participation in two upcoming investor conferences: the Goldman Sachs Annual Healthcare Conference (June 9-11, Miami, FL) and the J.P. Morgan European Healthcare Conference (June 12, London, U.K.). Riad Sherif, MD, CEO, will attend both events and engage in discussions. The company will also hold one-on-one meetings with interested investors. De...
06-03 08:00
美股大行评级 | 潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
05-10 10:00
Chardan Capital Maintains Buy on Oculis Holding, Raises Price Target to $33
Chardan Capital analyst Daniil Gataulin maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $28 to $33.
05-09 18:43
Oculis Holding Q1 EPS $(0.69) Misses $(0.43) Estimate
Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.43) by 60.47 percent. This is a 56.82 percent decrease over losses of $(0.44) per share from
05-09 05:13
